Singapore Immunology Network Teams Up with Swiss Cytos In Race To Develop mABs For HFMD
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Singapore Immunology Network, part of Singapore's Agency for Science Technology and Research, and Swiss company Cytos Biotechnology will collaborate to speed up development of fully human monoclonal antibodies for Enterovirus 71, one of the two most common viruses responsible for hand, foot and mouth disease
You may also be interested in...
SingVax Merges With Inviragen To Raise $15 Million In Series-A Financing For Vaccines To Fight Infectious Disease
SINGAPORE - U.S.-based Inviragen and Singapore-based SingVax unveiled plans to merge their companies' vaccine pipelines to form a new entity known as Inviragen (Singapore) to develop vaccines for a range of infectious diseases including dengue fever, Japanese encephalitis and hand, foot and mouth disease
SingVax Merges With Inviragen To Raise $15 Million In Series-A Financing For Vaccines To Fight Infectious Disease
SINGAPORE - U.S.-based Inviragen and Singapore-based SingVax unveiled plans to merge their companies' vaccine pipelines to form a new entity known as Inviragen (Singapore) to develop vaccines for a range of infectious diseases including dengue fever, Japanese encephalitis and hand, foot and mouth disease
Sinovac Beefs Up R&D To Bring Vaccines Into Clinical Trials To Prepare For Healthcare Reform
SHANGHAI - Chinese vaccine maker Sinovac said it will invest heavily in R&D over the next three years to prepare for China's ongoing healthcare reforms and to reduce the impact of the global financial crisis, during a conference call with investors and analysts on April 9